Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2024-03-22 Board/Management Inform…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of new outside directors for Daewon Pharmaceutical Co., Ltd. This falls under the category of Board/Management Information, specifically regarding changes in the board composition.
2024-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate) and key financial highlights (assets, liabilities, revenue, profit) for both consolidated and separate financial statements. While it contains financial data, it is a formal notification of the audit report's submission to the regulatory body (KRX) rather than the full annual report itself. Therefore, it is classified as an Audit Report/Information document. FY 2023
2024-03-14 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Daewon Pharmaceutical, covering the fiscal years 2022 and 2023. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. While it contains financial data, it is specifically the formal audit report issued by an accounting firm (Samjong KPMG) rather than a full Annual Report (10-K) or a simple earnings release. Therefore, it is classified as an Audit Report. FY 2023
2024-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daewon Pharmaceutical. It contains the agenda for the 63rd Annual General Meeting, including financial statement approval, director appointments, and remuneration limits. While it contains management information and business outlooks (which are typical for proxy materials), the primary purpose of this document is to formally notify shareholders of the upcoming meeting and provide the necessary information for them to vote. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2024-03-07 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Daewon Pharmaceutical regarding its 'Compliance Program' (CP) and anti-corruption management system (ISO37001). It details past performance and future operational plans for corporate governance and ethical compliance. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a formal regulatory announcement filed with the exchange (KRX), it falls under the 'Regulatory Filings' category.
2024-02-29 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Daewon Pharmaceutical. It outlines the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, dividend proposals, and the appointment of directors. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2024-02-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.